Shares in German drug discovery company Evotec tumbled on Thursday after Berenberg downgraded the stock to 'sell' from 'hold', citing a significant downgrade to the company's full-year guidance. The broker slashed its price target, warning that near-term revenue visibility had deteriorated sharply. Evotec's stock fell as much as 8% on the Frankfurt exchange, dragging the STOXX Europe 600 Health Care index down 0.6%.
The downgrade follows Evotec's revised outlook issued earlier this week, in which the company pointed to delayed partnership milestones and weaker-than-expected demand from large pharmaceutical clients. Berenberg analysts noted that the guidance cut 'raises fundamental questions about the pace of recovery' and suggested that margin pressures could persist for the remainder of the year. Other brokers are expected to review their ratings in coming days.
For UK investors, the news adds to a cautious tone in the life sciences sector, which has been under pressure from rising interest rates and tighter biotech funding. While Evotec is not listed on the FTSE 100, its performance influences European healthcare exchange-traded funds (ETFs) popular among British pension and ISA holders. The broader FTSE All-Share Index edged down 0.2% on Thursday, with healthcare names among the laggards.
Analysts at Peel Hunt commented that the Evotec downgrade 'reflects a wider trend of cautious spending by big pharma', which could weigh on contract research organisations (CROs) and drug discovery firms across Europe. They added that UK-listed peers such as Abcam and Oxford Nanopore may face similar scrutiny if client budgets tighten further. The sector's forward price-to-earnings ratio has contracted by roughly 12% since the start of 2026.
The development underscores the fragility of the biotech funding environment, which has yet to recover fully from the 2022-2023 downturn. With central bank rates still elevated, speculative investment in early-stage drug development remains subdued. For now, Berenberg's move signals that even established drug discovery platforms are not immune to the funding squeeze.